Fluorodeoxyglucose PET/Computed Tomography in Multimodality and Theranostic Workflows.

Authors

Yogita Khandelwal, Komal Bishnoi, Bela Jain, Rakesh Kumar

Published in

PET clinics. Aug 10, 2026. Epub Aug 10, 2026.

Abstract

Theranostics, the integration of diagnostic imaging and targeted radionuclide therapy, has transformed oncological practice. While receptor-targeted tracers such as somatostatin receptor PET/computed tomography (CT) and prostate-specific membrane antigen PET/CT anchor most theranostic workflows, 18F-fluorodeoxyglucose (FDG) PET/CT retains an indispensable role across the spectrum of theranostic diseases. FDG PET images glucose metabolism and thereby captures biological information that receptor-targeted tracers cannot. This review synthesizes current evidence, guideline recommendations, and emerging applications, including total-body PET, AI-assisted quantification, radiomics, and novel fibroblast activation protein inhibitor targeted theranostics, to define the evolving position of FDG-PET/CT as a gatekeeper in the theranostic oncological workflow.

PMID:
42575751
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.